3 Reasons Rite Aid Corporation's Stock Could Rise

Could Rite Aid's summer doldrums soon end?

Sep 5, 2014 at 9:01AM

Rite Aid Corporation's (NYSE:RAD) stock is on a roll. It's just not a good one.

Over the past three months, shares of the large pharmacy retailer have dropped around 28%. That's the bad news. The good news is that the stock is still up more than 20% year-to-date thanks to a fantastic run from January through early June. Could the momentum change for Rite Aid? Here are three reasons the stock could rise again -- although it's important to note that no one has a crystal ball (even if everything goes right for the company, a more general market correction could still cause shares to decline).

Rite Aid

Source: FoolEditorial on Flickr 

1. Generics

Never underestimate the importance of generic drugs to the financial health of pharmacy chains. Rite Aid's stock decline was precipitated in part by the lack of enough generic drug savings to offset lower reimbursement rates. One key factor for this dilemma came from timing issues with the company's new purchasing arrangement with McKesson

The nice thing about timing issues is that they eventually go away. Rite Aid CEO John Standley stated in June that savings from the McKesson deal will build up in the company's fiscal second quarter, which ended in August. The extent of the positive impact won't be known until Rite Aid announces its financial results in a couple of weeks, but his confidence in the advantages from the agreement seems well-placed. 

It's also simply a matter of time for more good news on the generics front. Rite Aid's initial financial projections counted on the availability of generic Nexium earlier this year. The launch of the generic version of the blockbuster heartburn drug has been delayed, however, due to Ranbaxy Laboratory's problems winning FDA approval. Ranbaxy is scrambling to resolve the manufacturing facility issues behind the delay. If it succeeds in doing so, Rite Aid will benefit. 

2. Wellness
Wellness should help Rite Aid from several angles. First, the company's Wellness concept stores boast higher same-store sales and prescription growth than its other stores. At the end of May, Rite Aid counted 1,325 Wellness stores -- 29% of its locations. The pharmacy retailer plans to remodel 450 stores to support the Wellness model this fiscal year, which should drive more dollars to the bottom line. 

Second, Rite Aid's Wellness+ customer loyalty program has potential to pay even greater dividends. This program provides exclusive savings and wellness benefits to members. The Wellness 65+ program includes nearly 2 million seniors in its ranks. 

Third, the company should reap rewards from its big push for Americans to get flu shots. Flu season is rapidly approaching and could drive more customers to Rite Aid stores. 

Rite Aid could also be a beneficiary of a wellness decision by rival CVS Health. CVS recently removed all tobacco products from its stores -- a move that could cost the company $2 billion. Those dollars could gravitate to Rite Aid as cigarette smokers and tobacco users change their pharmacy shopping destinations. 

3. Expectations
Near-term expectations have been lowered for Rite Aid since the company announced disappointing financial results last quarter. The stock's fall reflects this reality. However, long-term expectations are still quite positive.

Thomson Financial Network polled nine analysts who cover Rite Aid. On average, these analysts project earnings growth for Rite Aid to be five times higher than the industry as a whole this year and significantly higher over the next five years as well. These growth projections give the stock a price-to-earnings-to-growth, or PEG, ratio of 0.45. That's the kind of level that would make legendary investor Peter Lynch practically drool.

Are those growth estimates reasonable? I think so. Health reform continues to be a boon for Rite Aid, particularly in states that expanded Medicaid. The aging of Americans is another macro trend that works to the pharmacy chain's favor.

The above factors could easily help Rite Aid's stock to rebound. On the other hand, they might not make a huge difference immediately.

Rite Aid's arrangement with McKesson and the anticipated launch of generic Nexium should yield benefits. The various Wellness initiatives (including CVS Health's) should prove quite helpful. But in both cases, the timing of when the positives begin to mount up is difficult to predict. And lowered near-term expectations can overrule higher long-term expectations for longer than you might think.

All that being said, our focus at The Motley Fool is on the long run. If that's your time horizon, Rite Aid could be a stock to seriously consider.

Leaked: This coming blockbuster will make even Rite Aid jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Keith Speights has no position in any stocks mentioned. The Motley Fool recommends CVS Health and McKesson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information